Session » Posters: Clinical and Therapeutic II

Date: Friday, March 31, 2023

Time: 5:00PM-6:00PM

Meeting: 2023 Pediatric Rheumatology Symposium

5:00PM-6:00PM: Abstract Number: 117

A Descriptive Study of Patients with Multisystem Inflammatory Syndrome in Children

5:00PM-6:00PM: Abstract Number: 091

Achieving Remission in Childhood-onset Systemic Lupus Erythematosus: Rapid Implementation of an EMR-integrated Dashboard to Measure Disease Activity and Remission Rates

5:00PM-6:00PM: Abstract Number: 112

Adverse Childhood Experiences: Prevalence and Relationship to Disease in Childhood-onset Lupus

5:00PM-6:00PM: Abstract Number: 105

Awareness of Multisystem Inflammatory Syndrome in Children Among U.S. Parents: A Cross-Sectional Survey

5:00PM-6:00PM: Abstract Number: 106

Caregivers’ Perspectives on Barriers to Care in Juvenile Localized and Systemic Scleroderma

5:00PM-6:00PM: Abstract Number: 098

Characterization of Pulmonary Nodules in Juvenile-onset Systemic Sclerosis: A Single Center Case-Series

5:00PM-6:00PM: Abstract Number: 116

Clinical Significance of Anti-Scl-70 Antibodies in Pediatric Lupus Patients: A Single Center Cohort

5:00PM-6:00PM: Abstract Number: 114

Clinical Significance of SSA and SSB Antibodies in Pediatric SLE Patients: A Single Center Cohort

5:00PM-6:00PM: Abstract Number: 103

Clinical, Serologic, and Imaging Findings of Rhupus Syndrome in the Pediatric Population: A Systematic Literature Review

5:00PM-6:00PM: Abstract Number: 093

Comparison Between Induction with Rituximab and Cyclophosphamide in Treatment of Childhood-Onset ANCA-Associated Vasculitis

5:00PM-6:00PM: Abstract Number: 096

DADA2 – a Case Series from North India

5:00PM-6:00PM: Abstract Number: 115

Development of an Electronic Clinical Phenotype to Identify Potential Study Subjects with Juvenile Arthritis

5:00PM-6:00PM: Abstract Number: 108

Development of Mental Health Guidance Statements for Pediatric Rheumatology

5:00PM-6:00PM: Abstract Number: 123

Development of Specific Classification Criteria for Juvenile System Sclerosis Patients: A Scoping Review

5:00PM-6:00PM: Abstract Number: 101

Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity

5:00PM-6:00PM: Abstract Number: 126

Facilitating Peer-to-Peer Conversations Around Key Clinical Trial Recruitment Barriers in the Limit-JIA Trial Using Low-Fidelity Video Capture

5:00PM-6:00PM: Abstract Number: 124

JIA-Associated TMJ Arthritis, Idiopathic Condylar Resorption or Anterior Disc Displacement – a Care Provider Survey

5:00PM-6:00PM: Abstract Number: 122

Juvenile Arthritis in Minnesota: Geospatial Variability and Environmental Exposures in Juvenile Idiopathic Arthritis

5:00PM-6:00PM: Abstract Number: 119

Laser Flare Photometery in the Pediatric Rheumatology Clinic as a Screening Tool for Juvenile Idiopathic Arthritis Associated Uveitis

5:00PM-6:00PM: Abstract Number: 109

Long-term Safety of Biologics versus Conventional Synthetic Treatments in Systemic Juvenile Idiopathic Arthritis Patients

5:00PM-6:00PM: Abstract Number: 125

Measurable Outcomes of an Ophthalmology and Rheumatology Coordinated Care Clinic

5:00PM-6:00PM: Abstract Number: 110

Medications Affect Antibody Responses to COVID-19 Vaccinations in Children with Autoimmune Diseases

5:00PM-6:00PM: Abstract Number: 111

Monitoring for Hypogammaglobulinemia After B-Cell Therapy in an Academic Pediatric Center

5:00PM-6:00PM: Abstract Number: 102

Preliminary Results from a Survey of Psychological Resilience Among JIA Patients

5:00PM-6:00PM: Abstract Number: 104

Prevalence of Celiac Disease Among Children and Adolescents with Systemic Lupus Erythematosus (SLE)

5:00PM-6:00PM: Abstract Number: 092

Procalcitonin Levels in Patients with Juvenile Dermatomyositis Compared to Healthy Controls

5:00PM-6:00PM: Abstract Number: 113

Proportion of Patients with a Polyphasic Disease Course in Systemic-onset Juvenile Idiopathic Arthritis May Be Higher in the Age of Cytokine Inhibitors

5:00PM-6:00PM: Abstract Number: 094

Provider Assessment of the Temporomandibular Joint in Juvenile Idiopathic Arthritis

5:00PM-6:00PM: Abstract Number: 090

Safety Outcomes of Combined Biologics Use in Pediatric Rheumatology: A Single Center Experience

5:00PM-6:00PM: Abstract Number: 118

Serum Hepatocyte Growth Factor in Children with Juvenile Idiopathic Arthritis

5:00PM-6:00PM: Abstract Number: 097

Survey of Covid-19 Immunization and Infection in Patients with Systemic Juvenile Idiopathic Arthritis and Adult Onset Still’s Disease

5:00PM-6:00PM: Abstract Number: 095

Systemic Juvenile Idiopathic Arthritis Associated Lung Disease in Europe

5:00PM-6:00PM: Abstract Number: 120

The Brazilian Registry of Juvenile Dermatomyositis (JDM): I- Onset Clinical Features and Disease Activity Scores by DAS-20 over 2-Years-Follow Up

5:00PM-6:00PM: Abstract Number: 100

The Brazilian Registry of Juvenile Dermatomyositis (JDM): II – A Longitudinal Assessment of Muscle Strength by Manual Muscle Test (MMT) and Childhood Myositis Assessment Scale (CMAS) Tools

5:00PM-6:00PM: Abstract Number: 121

The Effectiveness of Tonsillectomy in Periodic Fever, Aphthous Ulcer, Pharyngitis, and Adenitis Syndrome in Pediatric Patients

5:00PM-6:00PM: Abstract Number: 099

The Impact of the COVID-19 Pandemic on Juvenile Dermatomyositis

5:00PM-6:00PM: Abstract Number: 107

Validation of Serious Adverse Event Reporting in a Multicenter Registry

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].